Go to the profile of Inotrem

Inotrem

 

About Inotrem

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide (LR12), with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases

Therapeutic Areas

Inflammation

Technologies

Drug delivery

Company Type

Biotechnology – R&D services

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

December 2019